Multiple Sclerosis
EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States
Published in Drug Law Weekly, October 13th, 2009
EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS). Cladribine Tablets has the potential to be the first orally administered disease-modifying therapy available for people living with relapsing MS, as all disease-modifying therapies currently approved for the treatment of MS are parenteral therapies.
"As a leader in the area of neurodegenerative diseases, we continue to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2009-10-13)
More Articles from Drug Law Weekly
- Alexza Pharmaceuticals, Inc.
Alexza to Raise $19.7 Million in Private Placement - Bionovo, Inc.
Bionovo Announces Pricing of Securities Offering - Biopharmaceuticals
Keryx Biopharmaceuticals, Inc. to Raise $20 Million in Registered Direct Offering - Center for Justice & Democracy
National Consumer Groups Announce Urgent New Ads Asking Congress to Oppose Medical Malpractice Limits - Clinical Trial Research
More Than 100 Organizations Support Bill to Boost Participation in Clinical Trials for Rare Diseases - Emergency Medicine
Stephen W. Borron, M.D., Named Medical Editor-In-Chief of ToxED - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
